<span item_type="fundamental" item_id="72030b2109fa41edefb0d31f8207d021" counter_id="ST/US/SLXNW" env="prod"></span><span item_type="announcement" item_id="581965436151927809" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -2.88.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -3.331 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Research and Development Expenses</strong>: $3,765 thousand for the nine months ended September 30, 2025, compared to $4,944 thousand for the same period in 2024. The decrease was mainly due to a reduction in non-cash share-based compensation expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003753/zk2533926.htm"></span></li><li><strong>General and Administrative Expenses</strong>: $3,461 thousand for the nine months ended September 30, 2025, compared to $5,727 thousand for the same period in 2024. The decrease was primarily due to a reduction in non-cash share-based compensation expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003753/zk2533926.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Operating Loss</strong>: $7,226 thousand for the nine months ended September 30, 2025, compared to $10,671 thousand for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003753/zk2533926.htm"></span></li><li><strong>Net Loss</strong>: $7,500 thousand for the nine months ended September 30, 2025, compared to $14,772 thousand for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003753/zk2533926.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $7,803 thousand for the nine months ended September 30, 2025, compared to - $5,470 thousand for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003753/zk2533926.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $15,861 thousand for the nine months ended September 30, 2025, compared to $2,920 thousand for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003753/zk2533926.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Cash and Cash Equivalents</strong>: $9,243 thousand as of September 30, 2025, compared to $1,187 thousand as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003753/zk2533926.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to continue investing in research and development to develop SIL204, including hiring additional employees and continuing the research and development of that product candidate. The company expects that its research and development expenses will continue to increase in the future.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003753/zk2533926.htm"></span></li><li><strong>Non-Core Business</strong>: The company has entered into an At The Market Offering Agreement to raise up to $13,170,000 through sales of ordinary shares, which will be used to finance ongoing operations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003753/zk2533926.htm"></span></li></ul><h3>Priority</h3><ul><li>The company is focused on maintaining compliance with Nasdaq listing standards to support its ability to fund operations through equity financings.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003753/zk2533926.htm"></span></li></ul>

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0